# Glen Clova Scientific

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glen-clova-scientific

- Industry: Biotechnology
- Headquarters: Glasgow, UK
- Website: www.glenclovascientific.com
- Total disclosed funding: $3.6M
- Latest round: Seed (Apr 25, 2024)
- Investors on record: 4

## About

Based in Glasgow, UK, and founded in 2022 by Steven Powell and John Foerster, Glen Clova Scientific Limited, a.k.a. Glen Clova Scientific operates as a biotechnology company that develops and manufactures biologic drugs for treating chronic inflammatory and autoimmune disorders. In April 2023, Glen Clova Scientific Limited raised GBP 2.5 million in seed funding led by Norcliffe Capital, with participation from DSW Ventures, TRICAPITAL, and Scottish Enterprise. The round was part of a larger GBP 4 million seed funding.

Glen Clova Scientific focuses on developing active biologic drugs with a platform design featuring proprietary VLP scaffolds and chaperone-assisted epitope proteins. The company’s pipeline includes GCS001, GCS002, and GCS003, which target dermatological and respiratory indications with validated safety and efficacy. With advantages like a single cell bank for epitope proteins and a streamlined downstream process, Glen Clova Scientific's pipeline has made advancements in healthcare, addressing unmet needs with high immunogenicity.

The company plans to use its proceeds from April 2024 funding to advance the preclinical development of its three initial drug candidates.

## Funding rounds

- Seed, Apr 25, 2024, $3.6M — Scottish Enterprise, Norcliffe Capital, TRICAPITAL, DSW Ventures

## Investors

- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Seed
- Norcliffe Capital (https://capitalatlas.ai/funds/norcliffe-capital) — Seed
- TRICAPITAL (https://capitalatlas.ai/funds/tricapital) — Seed
- DSW Ventures (https://capitalatlas.ai/funds/dsw-ventures) — Seed